- Home
- MAC vs APGE Comparison
MAC vs APGE Comparison
Compare MAC & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAC | APGE |
|---|---|---|
| Founded | 1964 | 2022 |
| Country | United States | United States |
| Employees | 2845 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.7B |
| IPO Year | 1994 | 2023 |
Fundamental Metrics
Financial Performance| Metric | MAC | APGE |
|---|---|---|
| Price | $18.75 | $73.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 11 |
| Target Price | $20.25 | ★ $101.20 |
| AVG Volume (30 Days) | ★ 1.5M | 706.6K |
| Earning Date | 05-11-2026 | 03-02-2026 |
| Dividend Yield | ★ 3.75% | N/A |
| EPS Growth | ★ 11.36 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,013,983,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.34 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.43 | N/A |
| 52 Week Low | $12.48 | $26.20 |
| 52 Week High | $20.93 | $84.56 |
Technical Indicators
Market Signals| Indicator | MAC | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 46.21 | 52.70 |
| Support Level | $17.81 | $73.06 |
| Resistance Level | $18.95 | $79.29 |
| Average True Range (ATR) | 0.60 | 4.17 |
| MACD | -0.12 | 0.19 |
| Stochastic Oscillator | 35.95 | 48.71 |
Price Performance
Historical ComparisonAbout MAC Macerich Company (The)
Macerich invests in premium mall assets. The company owns 27 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with a power center and seven other real estate assets. The company's total portfolio has 39.9 million square feet of gross leasable area and averaged $867 sales per square foot over the 12 months ended in September 2025.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.